Fabio Artosi | Medicine and Dentistry | Young Scientist Award

Dr. Fabio Artosi completed his secondary education at the State Classical High School “Piero Gobetti” in Fondi, Italy, graduating with a diploma awarded with full marks, a testament to his excellence in humanities, languages, and analytical thinking. He then pursued his studies at the Tor Vergata University of Rome, where he obtained a single-cycle Master’s degree in Medicine and Surgery with the highest honors, earning praise for his experimental thesis on the characterization of unknown-primary melanoma in light of new therapeutic options, a multicenter study that combined rigorous research methodology with clinical application. Shortly after, he achieved his national medical license and was registered with the Medical Doctors’ Register of the Province of Latina. His postgraduate path began with a scholarship in Medical Oncology at the Federico II University of Naples, where he refined his expertise in the clinical management of oncological patients. He was subsequently selected for the specific training course in General Medicine, further broadening his clinical scope. Continuing his specialization, he received a postgraduate scholarship in Dermatology and Venereology at Tor Vergata University, where he remains actively engaged. Currently, as a PhD student in Medical-Surgical Biotechnologies and Translational Medicine, he focuses on experimental dermatology, translational oncology, and epidemiology, integrating research excellence with patient-centered car.

Experience

Dr. Artosi’s career integrates direct patient care with high-impact research. Following his medical qualification in 2020, he undertook a postgraduate scholarship in Medical Oncology at Federico II University of Naples, where he gained advanced clinical skills in tumor diagnosis, systemic therapies, and patient follow-up.He entered the General Medicine training program while securing a dermatology scholarship at Tor Vergata University, immersing himself in the management of complex dermatological cases including autoimmune, inflammatory, and neoplastic skin diseases.He has been actively involved in multicenter clinical trials on biologics, immunotherapies, and targeted dermatological treatments, contributing to studies on psoriasis, hidradenitis suppurativa, actinic keratosis, chronic urticaria, and skin cancer prevention. His clinical expertise is complemented by strong dermoscopic, histopathological, and research protocol development skills. Internationally recognized for his scientific contributions, Dr. Artosi has presented at major dermatology and oncology conferences, including SIDEMAST and ADOI congresses, often as an invited speaker. His research output covers both real-life clinical studies and translational investigations into molecular biomarkers, immune modulation, and drug response patterns. Currently, as a PhD researcher, he continues to merge clinical insights with laboratory innovation, aiming to improve therapeutic strategies and patient outcomes in dermatology and related fields.

Honors and Awards

Dr. Fabio Artosi completed his secondary education at the State Classical High School “Piero Gobetti” in Fondi, Italy, graduating with a diploma awarded with full marks, a testament to his excellence in humanities, languages, and analytical thinking. He then pursued his studies at the Tor Vergata University of Rome, where he obtained a single-cycle Master’s degree in Medicine and Surgery with the highest honors, earning praise for his experimental thesis on the characterization of unknown-primary melanoma in light of new therapeutic options, a multicenter study that combined rigorous research methodology with clinical application. Shortly after, he achieved his national medical license and was registered with the Medical Doctors’ Register of the Province of Latina. His postgraduate path began with a scholarship in Medical Oncology at the Federico II University of Naples, where he refined his expertise in the clinical management of oncological patients. He was subsequently selected for the specific training course in General Medicine, further broadening his clinical scope. Continuing his specialization, he received a postgraduate scholarship in Dermatology and Venereology at Tor Vergata University, where he remains actively engaged. Currently, as a PhD student in Medical-Surgical Biotechnologies and Translational Medicine, he focuses on experimental dermatology, translational oncology, and epidemiology, integrating research excellence with patient-centered care.

Research Focus

Dr. Artosi’s research lies at the intersection of dermatology, oncology, and translational medicine. His primary interests include the epidemiology, pathogenesis, and clinical management of skin cancers (both melanoma and non-melanoma), with an emphasis on prevention strategies, biomarker discovery, and personalized treatment. He has contributed significantly to studies evaluating biologic agents in psoriasis, hidradenitis suppurativa, and psoriatic arthritis, particularly in complex cases with metabolic or oncological comorbidities. A key part of his work addresses inflammatory skin disorders, integrating insights from immunology to optimize biologic and small-molecule therapy outcomes. He is also involved in real-world evidence studies, capturing treatment patterns, safety profiles, and patient-reported outcomes to inform clinical guidelines. His translational projects investigate molecular markers in tumor microenvironments, immune response modulation, and microbial colonization in chronic skin disease. Additionally, he has studied the dermatological manifestations of systemic diseases, including connective tissue disorders and HIV-associated conditions. With active roles in multicenter randomized controlled trials and investigator-initiated studies, Dr. Artosi is committed to bridging experimental science with practical dermatological care. His research goal is to develop therapeutic strategies that are both scientifically sound and clinically feasible, ultimately enhancing patient quality of life and long-term disease control.

Publications

Relationship between collagen disorders and hidradenitis suppurativa regarding two cases of Loeys-Dietz syndrome – European Journal of Pediatric Dermatology 
 A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients – Pharmaceuticals 
Mepolizumab induced palmoplantar psoriasis: A case report – World Journal of Clinical Cases 
Epidemiological and clinical analysis of exposure-related factors in non-melanoma skin cancer – Environmental Research 
Efficacy and safety of tildrakizumab in elderly patients – Journal of Dermatological Treatment 
Dermanyssus gallinae dermatitis in a young Italian woman – Italian Journal of Dermatology and Venereology 
Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin – Pharmaceuticals 
Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Psoriasis